MUC2 and mucinous neoplasm: We have previously published promising preclinical data demonstrating effective reduction of MAPK pathway-mediated MUC2 protein production and mucinous tumor growth in vitro and in vivo following treatment with MEK (MAP kinase/ERK kinase) inhibitors [15].